Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
You can also access detailed information by clicking Login in the website header.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
USA
Regulatory Approval:
Your Trustedworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Humira (adalimumab) is a biologic medicine — a fully human monoclonal antibody that targets and blocks tumor necrosis factor-alpha (TNF-alpha), a protein involved in driving inflammation in several chronic autoimmune and inflammatory conditions.
Humira is FDA-approved for the treatment of moderate to severe rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, moderate to severe chronic plaque psoriasis, hidradenitis suppurativa, and non-infectious uveitis.
By binding to and neutralizing TNF-alpha, Humira reduces the inflammatory cascade responsible for joint damage, skin lesions, and gastrointestinal or ocular inflammation, depending on the condition being treated.
Dosing varies by indication. For adult rheumatoid arthritis, the typical dose is 40 mg subcutaneously every other week, sometimes combined with methotrexate. Crohn's disease and ulcerative colitis typically use a higher induction dose followed by a maintenance schedule. The treating physician determines the exact regimen based on diagnosis, weight, and response to therapy.
Boxed Warning — Humira: Humira carries an FDA boxed warning for serious infections, including tuberculosis (TB), invasive fungal infections, and infections due to bacterial, viral, or other opportunistic pathogens, which have led to hospitalization and death. Patients should be tested for latent TB before starting therapy. The boxed warning also covers an increased risk of lymphoma and other malignancies, including a rare hepatosplenic T-cell lymphoma reported in adolescent and young adult patients, primarily with Crohn's disease or ulcerative colitis treated with a TNF blocker in combination with azathioprine or 6-mercaptopurine.
Humira increases the risk of serious infections. Do not initiate in patients with an active infection, including localized infections.
Cases of malignancy, including lymphoma, have been reported in patients treated with TNF blockers.
TNF blockers can cause reactivation of hepatitis B virus in chronic carriers. Screen patients for HBV infection before starting treatment.
New onset or worsening congestive heart failure has been reported. Use with caution in patients with heart failure.
TNF blockers have been associated with new onset or exacerbation of central nervous system demyelinating disorders.
Serious allergic reactions and lupus-like syndrome have been reported.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant, cold-chain conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
Humira (adalimumab) received FDA approval in December 2002 and has since become one of the most widely prescribed biologic therapies globally for autoimmune and inflammatory conditions, manufactured by AbbVie.
Import of Humira through a Named Patient Program requires a valid prescription from the treating specialist, relevant diagnostic and treatment history, and supporting clinical documentation as required by Indian regulatory authorities.
For patients with inflammatory bowel disease (Crohn's disease or ulcerative colitis) whose condition does not respond adequately to Humira, alternative biologics such as Entyvio (gut-selective) or Skyrizi (IL-23 inhibitor) may be considered by the treating gastroenterologist.
NPP sources Humira directly from AbbVie's authorized supply chain to ensure product authenticity and regulatory compliance.
Humira is sourced through verified, GDP-compliant cold-chain channels from AbbVie's authorized supply chain to ensure authenticity and quality.
Humira should be stored refrigerated at 2°C to 8°C. If refrigeration is not available, it may be stored at room temperature up to 25°C for a maximum of 14 days, protected from light. Do not freeze.
Once sourced, Humira is packed and transported under continuous cold-chain conditions to preserve product integrity throughout the import process, with tracking and updates provided at each stage of delivery to the patient or treating hospital in India.
Patients across India can access Humira through NPP's regulated import pathway, with specialists in major cities supporting the treatment process.
Leading rheumatology and gastroenterology centers in Mumbai support Humira treatment coordination.
Delhi's major hospitals assist patients with prescription support and documentation for Humira.
Bangalore's specialist network offers access to Humira for eligible autoimmune and inflammatory disease patients.
Chennai-based specialists coordinate Humira access alongside comprehensive care for rheumatologic and GI conditions.
Hyderabad's care institutions support patients pursuing Humira therapy.
Kolkata's specialist centers help coordinate documentation and treatment access for Humira.
Pune-based specialists assist with diagnosis confirmation and Humira treatment planning.
Ahmedabad's specialty hospitals support the import and treatment process for Humira.
Kochi's specialist units assist patients with the documentation needed for Humira access.
Chandigarh's care centers support Humira treatment coordination for patients from North India.
Jaipur's specialists help patients navigate the Humira access process.
Lucknow-based centers assist patients pursuing Humira therapy.
Bhubaneswar's institutions support access to Humira for eligible patients.
Guwahati's specialists help coordinate Humira access for patients across the Northeast.
Patients in other cities across India can also access Humira through NPP's nationwide coordination network.
Written By: Nitin Goswami, Senior Medical Content Writer
Last Updated: 09 September 2026
Sources: FDA • CDSCO
Medically Reviewed By: Shilpi Banerjee, Registered Pharmacist (M.Pharm)
Last Updated: 09 September 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message
